Hyperlipidemia : News
Print
Email
SaveHealthline's Premium Tools
Healthline Part D Plan Selector
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
|
... in adults with type 2 diabetes mellitus, and to reduce elevated LDL cholesterol in adults with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with a hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (a ...
|
|
... in the normotensives (hazard risk: 7.53; 95% CI: 3.39 to 16.77). In the normotensives, diabetes mellitus and hyperlipidemia were significant determinants of CP-LVH but not of SL-LVH. In all of the hypertensive subgroups (normotensives, ...
|
|
... and a former NFL players had a higher rate of impaired fasting glucose (45.8 percent vs. 23.8 percent) and hyperlipidemia (42.2 percent vs. 9.5 percent) than the controls. When researchers compared the former NFL players CAC scores to controls, they ...
|
|
... and former NFL players had a higher rate of impaired fasting glucose (45.8 percent vs. 23.8 percent) and hyperlipidemia (42.2 percent vs. 9.5 percent) than the controls. When researchers compared the former NFL players CAC scores to controls, they ...
|
|
... and former NFL players had a higher rate of impaired fasting glucose (45.8 percent vs. 23.8 percent) and hyperlipidemia (42.2 percent vs. 9.5 percent) than the controls. When researchers compared the former NFL players CAC scores to controls, they ...
|
|
... history of heart disease. The researchers concluded that: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major ...
|
|
... atin significantly reduced the occurrence of major cardiovascular events in people without high blood lipids (hyperlipidemia) but with elevated levels of high-sensitivity C-reactive protein levels. What does the NHS Knowledge
|
|
... and former NFL players had a higher rate of impaired fasting glucose (45.8 percent vs. 23.8 percent) and hyperlipidemia (42.2 percent vs. 9.5 percent) than the controls. When researchers compared the former NFL players CAC scores to controls, they ...
|
|
... and former NFL players had a higher rate of impaired fasting glucose (45.8 percent vs. 23.8 percent) and hyperlipidemia (42.2 percent vs. 9.5 percent) than the controls. When researchers compared the former NFL players CAC scores to controls, they ...
|
|
... between abnormal lipoprotein subfractions and increased cardiovascular risk in patients with mixed hyperlipidemia. Using the Vertical Auto Profile (VAP Test) and S3GGE(TM) particle methods, researchers from the recent study titled VAP II analysis of ...
|
|
... reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. Crestor is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult ...
|
|
... area of focus is on the discovery and development of product candidates to treat metabolic diseases such as hyperlipidemia and diabetes, among others. Although not a core focus of the Company, Metabasis has also discovered and is developing product ...
|
|
... of the disabling comorbidities you'd expect to see in an obese person-sleep apnea, diabetes, hypertension and hyperlipidemia. Essentially homebound, Sam carried a Bi-Pap machine and a grocery sack of medications, and he couldn't walk more than three ...
|
|
... fat accumulation especially in the stomach. A totally new, totally innovative approach to combating obesity, hyperlipidemia, and Type II diabetes. More product innovations from Nutraceuticals Intl. 13-Oct-2008 - Where in the world can I get that? ...
|
|
... Knowledge of effects of lipid lowering drugs on lipoprotein subclasses is useful. We treated subjects with hyperlipidemia sequentially with statins and fibrates, the 2 classes of lipid lowering therapy and studied changes in NMR lipoprotein ...
|
|
... fat accumulation especially in the stomach. A totally new, totally innovative approach to combating obesity, hyperlipidemia, and Type II diabetes. More product innovations from Nutraceuticals Intl. Product brochure 13-Oct-2008 - Where in the world ...
|
|
... reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult ...
|
 |
 |
Home | About | Health Experts | Careers | Site Map | Feedback | Help | Health Tools | Tell a Friend
Advertise | Terms of Use | Privacy Policy
Advertise | Terms of Use | Privacy Policy
Copyright © 2005 - 2008 Healthline Networks, Inc. All rights reserved.